Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Liabilities (2017 - 2025)

Protagonist Therapeutics' Total Liabilities history spans 9 years, with the latest figure at $53.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 22.97% year-over-year to $53.5 million; the TTM value through Dec 2025 reached $53.5 million, down 22.97%, while the annual FY2025 figure was $53.5 million, 22.97% down from the prior year.
  • Total Liabilities for Q4 2025 was $53.5 million at Protagonist Therapeutics, down from $56.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $73.3 million in Q2 2024 and bottomed at $21.3 million in Q4 2023.
  • The 5-year median for Total Liabilities is $46.7 million (2021), against an average of $46.6 million.
  • The largest annual shift saw Total Liabilities plummeted 49.07% in 2023 before it soared 226.36% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $47.7 million in 2021, then plummeted by 32.21% to $32.3 million in 2022, then plummeted by 34.18% to $21.3 million in 2023, then skyrocketed by 226.36% to $69.4 million in 2024, then dropped by 22.97% to $53.5 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Total Liabilities are $53.5 million (Q4 2025), $56.3 million (Q3 2025), and $50.0 million (Q2 2025).